Disposition of 7500 shares by Stephen Carey of ANI Pharmaceuticals at 55.79 subject to Rule 16b-3

AMPH Stock  USD 38.02  1.12  2.86%   
Under 54% of Amphastar's investor base is interested to short. The analysis of overall sentiment of trading Amphastar P stock suggests that many investors are impartial at this time. Amphastar's investing sentiment shows overall attitude of investors towards Amphastar P.
  
Filed transaction by ANI Pharmaceuticals Officer: Svp & Cfo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at thelincolnianonline.com
news
  
Disposition of 7500 common stock at 55.79 of ANI Pharmaceuticals by Stephen Carey on 17th of December 2024. This event was filed by ANI Pharmaceuticals with SEC on 2024-12-17. Statement of changes in beneficial ownership - SEC Form 4

Amphastar Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Amphastar can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Amphastar Fundamental Analysis

We analyze Amphastar's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amphastar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amphastar based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

Amphastar is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Amphastar P Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Amphastar stock to make a market-neutral strategy. Peer analysis of Amphastar could also be used in its relative valuation, which is a method of valuing Amphastar by comparing valuation metrics with similar companies.

Peers

Amphastar Related Equities

EVOEvotec SE   12.53   
0%
100.0%
PCRXPacira BioSciences,   1.30   
0%
10.0%
IRWDIronwood Pharmaceuticals   0.65   
0%
5.0%
ALKSAlkermes Plc   0.47   
0%
3.0%
PBHPrestige Brand   0.29   
0%
2.0%
SUPNSupernus Pharmaceuticals   0.06   
1.0%
0%
NBIXNeurocrine Biosciences   0.06   
1.0%
0%
COLLCollegium Pharmaceutical   0.17   
1.0%
0%
ANIPANI Pharmaceuticals   0.22   
1.0%
0%
PAHCPhibro Animal   0.37   
2.0%
0%
EOLSEvolus   1.29   
10.0%
0%

Complementary Tools for Amphastar Stock analysis

When running Amphastar's price analysis, check to measure Amphastar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amphastar is operating at the current time. Most of Amphastar's value examination focuses on studying past and present price action to predict the probability of Amphastar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amphastar's price. Additionally, you may evaluate how the addition of Amphastar to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
CEOs Directory
Screen CEOs from public companies around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Valuation
Check real value of public entities based on technical and fundamental data